Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor: AstraZeneca
Listed as NCT02558894, this PHASE2 trial focuses on Metastatic Pancreatic Ductal Adenocarcinoma and remains completed. Sponsored by AstraZeneca, it has been updated 13 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Mar 2022 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Dec 2021 — Jan 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Barcelona, Spain , Friedrichshafen, Germany , Groningen, Netherlands , Madrid, Spain , Montreal, Canada , München, Germany , New York, United States , Nijmegen, Netherlands , Oshawa, Canada and 7 more locations